Compare CDIO & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | DSS |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.3M |
| IPO Year | N/A | 2020 |
| Metric | CDIO | DSS |
|---|---|---|
| Price | $1.84 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.4K | ★ 60.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,085,000.00 |
| Revenue This Year | $171,906.75 | $1.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.97 | $0.36 |
| 52 Week High | $7.91 | $1.90 |
| Indicator | CDIO | DSS |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 46.70 |
| Support Level | $1.68 | $0.51 |
| Resistance Level | $2.16 | $1.05 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 0.00 | 22.30 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.